Skip Navigation


Hum. Reprod. Advance Access originally published online on November 16, 2007
Human Reproduction 2008 23(2):427-434; doi:10.1093/humrep/dem317
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
23/2/427    most recent
dem317v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by NyboeAndersen, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by NyboeAndersen, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial

A. NyboeAndersen1,10, P. Humaidan2, G. Fried3, J. Hausken4, L. Antila5, S. Bangsbøll1, P.E. Rasmussen6, S. Lindenberg7, H. Ejdrup Bredkjaer8, H. Meinertz The Nordic LH study group9,9

1 The Fertility clinics 4017, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark 2 Skive Hospital, Skive, Denmark 3 Karolinska University Hospital, Stockholm, Sweden 4 Haugesund Hospital, Haugesund, Norway 5 The Family Federation of Finland, Turku, Finland 6 Odense University Hospital, Odense, Denmark 7 Herlev University Hospital, Copenhagen, Denmark 8 Holbæk Hospital, Holbæk, Denmark 9 Hvidovre Hospital, Copenhagen, Denmark

10Correspondence address. Tel: +453-5451315/4976; Fax: +453-5454946; E-mail: anyboea{at}rh.hosp.dk

BACKGROUND: The purpose of this multicentre, multinational trial was to study whether rLH supplementation to recombinant FSH (rFSH) during the late follicular phase increased pregnancy rates.

METHODS: After down-regulation with nafarelin, 526 women were randomized on Day 1 of stimulation to use either rFSH (Gonal-F) alone (n = 261) or to continue after Day 6 of stimulation with both rFSH (Gonal-F) and rLH (Luveris) (n = 265) from Day 6. The starting dose of rFSH was 150–225 IU/day according to age below or above 35 years.

RESULTS: Ongoing pregnancy rate at week 10–12 was 28.7% after rFSH alone and 27.2% after rFSH + rLH. This showed no evidence of a difference. Administration of rLH significantly (P< 0.001) increased serum LH. Ongoing pregnancy rates in patients with low LH levels (<33 percentile) on Days 1 and 6 of stimulation showed no difference between the group treated with rFSH only (23.9% low Day 1 LH; 22.1% low Day 6 LH) versus rFSH + rLH (25.0% low Day 1 LH; 28.9% low Day 6 LH).

CONCLUSIONS: Supplementing rFSH with daily doses of 75–150 IU of rLH during the second half of the follicular phase showed no evidence of increasing the ongoing pregnancy rates in the general population. (ClinicalTrials.gov, trial number: KF02-035/03).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.